WallStreetZenWallStreetZen

NASDAQ: VCYT
Veracyte Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VCYT

Based on 9 analysts offering 12 month price targets for Veracyte Inc

Min Forecast
$44.00-4.8%
Avg Forecast
$57.78+25.01%
Max Forecast
$69.00+49.29%

Should I buy or sell VCYT stock?

Based on 9 analysts offering ratings for Veracyte Inc.

Strong Buy
Strong Buy
6 analysts 66.67%
Buy
1 analysts 11.11%
Hold
1 analysts 11.11%
Sell
0 analysts 0%
Strong Sell
1 analysts 11.11%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their VCYT stock forecasts and price targets.

VCYT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-15
lockedlocked$00.00+00.00%2026-09-09Find Out Why
lockedlocked$00.00+00.00%2026-08-04
lockedlocked$00.00+00.00%2026-08-04
lockedlocked$00.00+00.00%2026-08-04
Canaccord Genuity
Top 7%
94
HoldMaintains$50.00+11.63%2026-08-03
Needham
Top 17%
84
BuyMaintains$69.00+54.05%2026-07-31
Guggenheim
Top 1%
100
Strong BuyMaintains$65.00+45.12%2026-06-29Find out why
UBS
Top 44%
57
Strong BuyMaintains$52.00+16.10%2026-05-06

1 of 1

Forecast return on equity

Is VCYT forecast to generate an efficient return?

Company
11.84%
Industry
23.57%
Market
177.72%
VCYT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VCYT forecast to generate an efficient return on assets?

Company
11.06%
Industry
23.3%
VCYT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VCYT earnings per share forecast

What is VCYT's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$1.94+35.02%
Avg 2 year Forecast
$1.99+37.91%
Avg 3 year Forecast
$2.05+42.08%
VCYT's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

VCYT revenue forecast

What is VCYT's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$605.7M+7.79%
Avg 2 year Forecast
$672.0M+19.6%
Avg 3 year Forecast
$741.1M+31.9%
VCYT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VCYT earnings growth forecast

How is VCYT forecast to perform vs Biotechnology companies and vs the US market?

Company
12.35%
Industry
11.5%
Market
32.51%
VCYT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
VCYT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
VCYT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

VCYT revenue growth forecast

How is VCYT forecast to perform vs Biotechnology companies and vs the US market?

Company
9.64%
Industry
30.7%
Market
13.52%
VCYT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VCYT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VCYT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VCYT$44.79$57.78+29.00%Strong Buy
ABCL$11.71$15.71+34.19%Strong Buy
ACAD$20.44$30.92+51.29%Buy
LEGN$19.01$45.38+138.69%Buy
XENE$36.27$67.50+86.10%Strong Buy
View Top Biotech Stocks

Veracyte Stock Forecast FAQ

Is Veracyte Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: VCYT) stock is to Strong Buy VCYT stock.

Out of 9 analysts, 6 (66.67%) are recommending VCYT as a Strong Buy, 1 (11.11%) are recommending VCYT as a Buy, 1 (11.11%) are recommending VCYT as a Hold, 0 (0%) are recommending VCYT as a Sell, and 1 (11.11%) are recommending VCYT as a Strong Sell.

If you're new to stock investing, here's how to buy Veracyte stock.

What is VCYT's earnings growth forecast for 2026-2028?

(NASDAQ: VCYT) Veracyte's forecast annual earnings growth rate of 12.35% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.48%.

Veracyte's earnings in 2026 is $114,483,000.On average, 15 Wall Street analysts forecast VCYT's earnings for 2026 to be $156,303,698, with the lowest VCYT earnings forecast at $140,233,591, and the highest VCYT earnings forecast at $165,444,124. On average, 15 Wall Street analysts forecast VCYT's earnings for 2027 to be $159,647,953, with the lowest VCYT earnings forecast at $132,355,300, and the highest VCYT earnings forecast at $178,194,094.

In 2028, VCYT is forecast to generate $164,479,436 in earnings, with the lowest earnings forecast at $101,629,962 and the highest earnings forecast at $196,675,923.

What is VCYT's revenue growth forecast for 2026-2028?

(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 9.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.

Veracyte's revenue in 2026 is $561,900,000.On average, 15 Wall Street analysts forecast VCYT's revenue for 2026 to be $48,688,646,230, with the lowest VCYT revenue forecast at $46,481,920,664, and the highest VCYT revenue forecast at $50,477,339,995. On average, 15 Wall Street analysts forecast VCYT's revenue for 2027 to be $54,024,179,047, with the lowest VCYT revenue forecast at $50,553,711,189, and the highest VCYT revenue forecast at $57,458,471,075.

In 2028, VCYT is forecast to generate $59,580,786,373 in revenue, with the lowest revenue forecast at $54,394,780,317 and the highest revenue forecast at $63,898,572,535.

What is VCYT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VCYT) forecast ROA is 11.06%, which is lower than the forecast US Biotechnology industry average of 23.42%.

What is VCYT's Price Target?

According to 9 Wall Street analysts that have issued a 1 year VCYT price target, the average VCYT price target is $57.78, with the highest VCYT stock price forecast at $69.00 and the lowest VCYT stock price forecast at $44.00.

On average, Wall Street analysts predict that Veracyte's share price could reach $57.78 by Sep 15, 2027. The average Veracyte stock price prediction forecasts a potential upside of 29% from the current VCYT share price of $44.79.

What is VCYT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: VCYT) Veracyte's current Earnings Per Share (EPS) is $1.44. On average, analysts forecast that VCYT's EPS will be $1.94 for 2026, with the lowest EPS forecast at $1.74, and the highest EPS forecast at $2.06. On average, analysts forecast that VCYT's EPS will be $1.99 for 2027, with the lowest EPS forecast at $1.65, and the highest EPS forecast at $2.22. In 2028, VCYT's EPS is forecast to hit $2.05 (min: $1.26, max: $2.45).

What is VCYT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VCYT) forecast ROE is 11.84%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.